Moderna is set to pay Roivant up to $2.25 billion as part of a settlement that resolves a major patent lawsuit related to mRNA vaccine technology. This agreement brings significant financial benefits to Arbutus and Roivant, while enabling Moderna to avoid a potentially severe legal setback.